![How to Find Low-Competition Keywords with Semrush [Super Easy]](https://static.semrush.com/blog/uploads/media/73/62/7362f16fb9e460b6d58ccc09b4a048b6/how-to-find-low-competition-keywords-sm.png)
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on Wall Street's projections, several notable biotechs could see their shares soar in the next 12 months.Of course, it wouldn't be wise to rush to invest in these companies for that reason alone, but it might be worth looking deeper into what the Street considers severely undervalued drugmakers. Read on to learn more about four biotechs with price targets that imply significant upsides (based on prices as of Apr. 3) of between 50% and 543% in the next year.Of the pure-play gene editing specialists on the market, CRISPR Therapeutics (NASDAQ: CRSP) is one of the more prominent. In 2023, it earned approval for Casgevy, a therapy for two rare blood diseases with few treatment options. Casgevy became the first CRISPR-based medicine approved -- this technique earned its creators a Nobel prize in chemistry. However, CRISPR Therapeutics has been in free-fall mode since Casgevy's approval, partly because administering it is complex. The biotech has yet to record much sales from it.Continue reading
As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on Wall Street's projections, several notable biotechs could see their shares soar in the next 12 months.
Of course, it wouldn't be wise to rush to invest in these companies for that reason alone, but it might be worth looking deeper into what the Street considers severely undervalued drugmakers. Read on to learn more about four biotechs with price targets that imply significant upsides (based on prices as of Apr. 3) of between 50% and 543% in the next year.
Of the pure-play gene editing specialists on the market, CRISPR Therapeutics (NASDAQ: CRSP) is one of the more prominent. In 2023, it earned approval for Casgevy, a therapy for two rare blood diseases with few treatment options. Casgevy became the first CRISPR-based medicine approved -- this technique earned its creators a Nobel prize in chemistry. However, CRISPR Therapeutics has been in free-fall mode since Casgevy's approval, partly because administering it is complex. The biotech has yet to record much sales from it.
